Down-regulation of expression of interleukin-6 and its receptor results in growth inhibition of MCF-7 breast cancer cells

Anticancer Research

Volumn 31, Issue 9, 2011, Pages 2899-2906

  Jiang, Xian Peng ^a   Yang, Ding Cheng ^a   Elliott, Robert L ^a   Head, Jonathan F ^a  

^a The Mastology Research Institute   (United States)

Author keywords

Antisense; Breast cancer; Interleukin 6; Interleukin 6 receptor; MCF 7; Oligodeoxynucleotides

Indexed keywords

ANTISENSE OLIGODEOXYNUCLEOTIDE; INTERLEUKIN 6; INTERLEUKIN 6 ANTIBODY; INTERLEUKIN 6 RECEPTOR; MESSENGER RNA;

ARTICLE; BREAST CANCER; CANCER CELL; CANCER GROWTH; CANCER INHIBITION; CELL PROLIFERATION; DOWN REGULATION; GENE EXPRESSION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN SECRETION;

BASE SEQUENCE; BREAST NEOPLASMS; CELL LINE, TUMOR; DNA PRIMERS; DOWN-REGULATION; ELECTROPHORESIS, AGAR GEL; ENZYME-LINKED IMMUNOSORBENT ASSAY; FEMALE; HUMANS; INTERLEUKIN-6; RECEPTORS, INTERLEUKIN-6; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION;

EID: 80051616701     PISSN: 02507005     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (50)

1. Kishimoto T: The biology of interleukin-6. Blood 14: 1-10, 1990.
2. Kyle RA: Prognostic factors in multiple myeloma. Stem Cell (Dayt) 13(Suppl2): 56-63, 1995.
3. Seymour JF, Talpaz M, Hagemeister FB, Cabanillas F and Kurzrock R: Clinical correlates of elevated serum levels of interleukin-6 in patients with untreated Hodgkin's disease. Am J Med 102: 21-28, 1997. (Pubitemid 27089983)
4. Blay JY, Negrier S, Combaret V, Attali S, Goillot E, Merrouche Y, Mercatello A, Ravault A, Tourani JM and Moskovtckenko JF: Serum level of interleukin-6 as a prognosis factor in metastatic renal cell carcinoma. Cancer Res 52: 3317-3322, 1992.
5. Yoshida N, Ikemoto S, Narita K, Sugimura K, Wada S, Yasumoto R, Kishimoto T and Nakatani T: Interleukin-6, tumour necrosis factor alpha and interleukin-1beta in patients with renal cell carcinoma. Br J Cancer 86: 1396-1400, 2002. (Pubitemid 34548059)
6. Thiounn N, Pages F, Flam T, Tartour E, Mosseri V, Zerbib M, Beuzeboc P, Deneux L, Fridman WH and Debre B: IL-6 is a survival prognostic factor in renal cell carcinoma. Immunol Lett 58: 121-124, 1997. (Pubitemid 27348916)
7. Andrews B, Shariat SF, Kim JH, Wheeler TM, Slawin KM and Lerner SP: Preoperative plasma levels of interleukin-6 and its soluble receptor predict disease recurrence and survival of patients with bladder cancer. J Urol 167: 1475-1481, 2002. (Pubitemid 34132135)
8. Scambia G, Testa U, Benedetti PP, Foti E, Martucci R, Gadducci A, Perillo A, Facchini V, Peschle C and Mancuso S: Prognostic significance of interleukin-6 serum levels in patients with ovarian cancer. Br J Cancer 71: 354-356, 1995.
9. Tempfer C, Zeisler H, Sliutz G, Haeusler G, Hanzel E and Kainz C: Serum evaluation of interleukin-6 in ovarian cancer patients. Gynecol Oncol 66: 27-30, 1997. (Pubitemid 27329303)
10. Oka M, Yamamoto K, Takahashi M, Hakozaki M, Abe T, Iizuka N, Hazama S, Hirazawa K, Hayashi H, Tangoko A, Hirose K, Ishihara T and Suzuki T: Relationship between serum levels of interleukin-6, various disease parameters and malnutrition in patients with esophageal squamous cell carcinoma. Cancer Res 56: 2276-2280, 1996.
11. Haverty AA, Harmey JH, Redmond HP and Bouchier-Hayes DJ: Interleukin-6 up-regulates GP96 expression in breast cancer. J Surg Res 69: 145-149, 1997. (Pubitemid 27265841)
12. Yokoe T, Iino Y, Takei H, Horiguchi J, Koibuchi Y, Maemura M, Ohwada S and Morishito Y: Changes of cytokines and thyroid function in patients with recurrent breast cancer. Anticancer Res 17: 695-699, 1997. (Pubitemid 27105552)
13. Tamm I, Cardinale I and Sehgal P: Interleukin-6 and 12-O-tetradecanoyl phorbol-13-acetate act synergistically in inducing cell-cell separation and migration of human breast carcinoma cells. Cytokine 3: 212-223, 1991.
14. Hill RJ, Warren MK, Stenberg P, Levin H, Corash L, Drummond R, Bakers G, Levin F and Mok Y: Stimulation of megakaryocytopoiesis in mice by human recombinant interleukin-6. Blood 77: 42-48, 1991.
15. Ullmann CD, Schlom J and Greiner JW: Interleukin-6 increases carcinoembryonic antigen and histocompatibility leukocyte antigen expression on the surface of human colorectal carcinoma cells. J Immunother 12: 231-241, 1992.
16. Jiang XP, Yang DC, Elliott RL and Head JF: Interleukin-6 enhances tumor antigen expression in the MCF-7 human breast cancer cell line and breast cancer patients. Breast Cancer Res Treat 57: 95a, 1999.
17. Taga T, Hibi M, Hirata Y, Yamasaki K, Yasukawa K, Matsuda T, Hirano T and Kishimoto T: Interleukin-6 triggers the association of its receptor with a possible signal transducer, GP130. Cell 58: 573-581, 1989. (Pubitemid 19203542)
18. Kimura T, Wang J, Minamiguchi H, Fujiki H, Harada S, Okuda K, Kaneko H, Yokota S, Yasukawa K, Abe T and Sonoda Y: Signal through GP130 activated by soluble interleukin-6 receptor (IL-6R) and IL-6 or IL-6R/IL-6 fusion protein enhances ex vivo expansion of human peripheral blood-derived hematopoietic progenitors. Stem Cells 18: 444-452, 2000.
19. Sui X, Tsuji K, Ebihara Y, Tanaka R, Muraoka K, Yoshid AM, Yamada K, Yasukawa K, Taga T, Kishimoto T and Nakahata T: Soluble interleukin-6 (IL-6) receptor with IL-6 stimulates megakaryopoiesis from human CD34(+) cells through glycoprotein (GP)130 signaling. Blood 93: 2525-2532, 1999. (Pubitemid 29181184)
20. Yasukawa K, Hirano T, Watanabe Y, Muratani K, Matsuda T, Nakai S and Kishimoto T: Structure and expression of human cell stimulatory factor-2 (BSF-2/IL-6) gene. EMBO J 6: 2939-2949, 1987.
21. Schooltink H, Stoyan T, Lenz D, Schmitz H, Hirano T, Kishimoto T, Henrich P and Rose-John S: Structural and functional studies on the human hepatic interleukin-6 receptor. Molecular cloning and overexpression in HepG2 cells. Biochem J 277: 659-664, 1991.
22. Keller T and Ershler WB: Effect of IL-6 receptor antisense oligodeoxynucleotide on in vitro proliferation of myeloma cells. J Immunol 154: 4091-4098, 1995.
23. Badache A and Hynes NE: Interleukin-6 inhibits proliferation and, in cooperation with an epidermal growth factor receptor autocrine loop, increases migration of T47D breast cancer cells. Cancer Res 61: 383-391, 2001. (Pubitemid 32095742)
24. Steiner H, Godoy-Tundidor S, Rogatsch H, Berger AP, Fuchs D, Comuzzi B, Bartsch G, Hobisch A and Culig Z: Accelerated in vivo growth of prostate tumors that up-regulate interleukin-6 is associated with reduced retinoblastoma protein expression and activation of the mitogen-activated protein kinase pathway. Am J Pathol 162: 655-663, 2003. (Pubitemid 36267872)
25. Schneider MR, Hoeflich A, Fischer JR, Wolf E, Sordat B and Lahm H: Interleukin-6 stimulates clonogenic growth of primary and metastatic human colon carcinoma cells. Cancer Lett 151, 31-38, 2000. (Pubitemid 30155582)
26. Reittie JE, Yong KL, Panayiotidis P and Hoffbrand AV: Interleukin-6 inhibits apoptosis and tumour necrosis factor induced proliferation of B-chronic lymphocytic leukaemia. Leuk Lymphoma 22: 83-90, 1996. (Pubitemid 26177722)
27. Lu C and Kerbel RS: Interleukin-6 undergoes transition from paracrine growth inhibitor to autocrine stimulator during human melanoma progression. J Cell Biol 120: 1281-1288, 1993. (Pubitemid 23064182)
28. Koo AS, Armstrong C, Bochner B, Shimabukuro T, Tso C, Dekernion JB and Belldegrun A: Interleukin-6 and renal cell carcinoma: production, regulation, and growth effects. Cancer Immunol. Immunother 35: 97-105, 1992.
29. Xiao B, Jing B, Zhang YL, Zhou DY and Zhang WD: Tumor growth inhibition effect of hIL-6 on colon cancer cells transfected with the target gene by retroviral vector. World J Gastroenterol 6: 89-92, 2000. (Pubitemid 30093070)
30. Fontaine V, Mahieu M and Content J: Interferon-gamma and interleukin-6 inhibit proliferation in human melanoma cells by different signalling pathways. Melanoma Res 8: 24-30, 1998. (Pubitemid 28114298)
31. Kortylewski M, Heinrich PC, Mackiewicz A, Schniertshauer U, Klingmuller U, Nakajima K, Hirano T, Horn F and Behrmann I: Interleukin-6 and oncostatin M-induced growth inhibition of human A375 melanoma cells in STAT-dependent and involves up-regulation of the cyclin-dependent kinase inhibitor p27/KIP1. Oncogene 18: 3742-3753, 1999. (Pubitemid 29338507)
32. Nakajima K, Yamanaka Y, Nakae K, Kojima H, Ichiba M, Kiuchi N, Kitaoka T, Fukada T, Hini M and Hirano T: A central role for STAT3 in IL-6-induced regulation of growth and differentiation in M1 leukemia cells. EMBO J 15: 3651-3658, 1996. (Pubitemid 26239777)
33. Danforth DN Jr., and Sgagias MK: Interleukin-1 alpha and interleukin-6 act additively to inhibit growth of MCF-7 breast cancer cells in vitro. Cancer Res 53: 1538-1545, 1993.
34. Conze D, Weiss L, Regan PS, Bhushan A, Weaver D, Johnson P and Rincon M: Autocrine production of interleukin-6 causes multidrug resistance in breast cancer cells. Cancer Res 61: 8851-8858, 2001.
35. Honma S, Shimodaira K, Shimizu Y, Tsuchiya N, Saito H, Yanaihara T and Okai T: The influence of inflammatory cytokines on estrogen production and cell proliferation in human breast cancer cells. Endocr J 49: 371-377, 2002. (Pubitemid 34832311)
36. Fukada T, Hibi M, Yamanaka Y, Takahishi-Tezuka M, Fujitani Y, Yamaguchi T, Nakajima K and Hirano T: Two signals are necessary for cell proliferation induced by a cytokine receptor GP130: involvement of STAT3 in anti-apoptosis. Immunity 5: 449-460, 1996. (Pubitemid 26423473)
37. Hirano T: Molecular basis underlying functional pleiotropy of cytokines and growth factors. Biochem Biophys Res Commun 260: 303-308, 1999.
38. Leu CM, Wong FH, Chang C, Huang SF and Hu CP: Interleukin-6 acts as an antiapoptotic factor in human esophageal carcinoma cells through the activation of both STAT3 and mitogen-activated protein kinase pathways. Oncogene 22: 7809-7818, 2003. (Pubitemid 37485540)
39. Fukada T, Ohtani T, Yoshida Y, Shirogane T, Nishida K, Nakajima K, Hibi M and Hirano T: STAT3 orchestrates contradictory signals in cytokine-induced G1 to S cell-cycle transition. EMBO J 17: 6670-6677, 1998. (Pubitemid 28521800)
40. Horiguchi A, Oya M, Marumo K and Murai M: STAT3, but not ERKs, mediates the IL-induced proliferation of renal cancer cells, ACHN and 769P. Kidney Int 61: 926-938, 2002. (Pubitemid 34175461)
41. Bromberg JF, Wrzeszczynska MH, Devgan G, Zhao Y, Pestell RG, Albanese C and Darnell JE: STAT3 as an oncogene. Cell 98: 295-303, 1999. (Pubitemid 29380565)
42. Corada M, Liao F, Lindgren M, Lampugnani MG, Breviario F, Frank R, Muller WA, Hicklin DJ, Bohlen P and Dejana E: Monoclonal antibodies directed to different regions of vascular endothelial Cadherin extracellular domain affect adhesion and clustering of the protein and modulate endothelial permeability. Blood 97: 1679-1684, 2001. (Pubitemid 32217233)
43. Jiang, XP, Yang DC, Elliott RL and Head JF: Reduction in serum IL-6 after vaccination of breast cancer patients with tumor-associated antigens is related to estrogen receptor status. Cytokine 12: 458-465, 2000. (Pubitemid 30449843)
44. Jiang XP, Yang DC, Head JF and Elliott RL: All-trans-retinoic acid down-regulates interleukin-6 synthesis in human breast cancer. Proc Am Assoc Cancer Res 40: 63, 1999.
45. Jiang XP, Yang DC, Head JF and Elliott RL: Vaccination of breast cancer patients with autologous tumor-associated antigens results in reduction of serum interleukin-6. Proc Am Assoc Cancer Res 39: 356, 1998.
46. Head JF, Jiang XP, Yang DC and Elliott RL: Serum interleukin-6 (IL-6) concentration correlates with serum tumor marker CA15-3 concentration in breast cancer patients. Proc Am Soc Clin Oncol 18: 630a, 1999.
47. Zhou H, Beevers CS and Huang S: The targets of curcumin. Curr Drug Targets 12: 332-347, 2011.
48. Saydmohammed M, Joseph D and Syed V: Curcumin suppresses constitutive activation of STAT-3 by up-regulating protein inhibitor of activated STAT-3 (PIAS-3) in ovarian and endometrial cancer cells. J Cell Biochem 110: 447-456, 2010.
49. Park J, Ayyappan V, Bae EK, Lee C, Kim BS, Kim BK, Lee YY, Ahn KS and Yoon SS: Curcumin in combination with bortezomib synergistically induced apoptosis in human multiple myeloma U266 cells. Mol Oncol 2: 317-326, 2008.
50. Cohen AN, Veena MS, Srivatsan BS and Wang MB: Suppress of interleukin-6 and -8 production in head and neck cancer cells with curcumin via inhibition of Ikappa beta kinase. Arch Otolaryngol Head Neck Surg 135: 190-197, 2009.